1. Introduction {#sec1}
===============

Cancer imposes a serious disease burden worldwide, with high incidence and mortality \[[@B1]\]. The international agency for research on cancer affirmed that, as the world\'s population ages, the number of cancer deaths worldwide will continue to increase \[[@B2]\]. The top 10 tumors were cancers of the lung, esophagus, liver, cervix, stomach, breast, colon-rectum, lymphocytes, nasopharynx, and ovary. Five-year survival rates for all-combined cancer were only 30.82% \[[@B3]\]. The primary methods of cancer treatment are surgical treatment, chemotherapy, and radiotherapy; however, even with all these advances, a large number of patients still have poor prognosis \[[@B4]--[@B6]\].

Considering the high incidence of cancer and its poor prognosis, it would be of great significance to find effective clinical predictors of mortality in cancer. Recently, several studies have reported that red blood cell distribution width (RDW) was associated with mortality in various cancers; however, there was substantially less evidence regarding RDW and all-combined cancer \[[@B7]--[@B10]\]. Many factors that could affect long-term prognosis of cancers have been identified, but there are relatively few identified factors affecting short-term prognosis.

The red blood cell distribution width (RDW) is a parameter that reflects the degree of heterogeneity of erythrocyte volume; it is traditionally used in hematology laboratories to help classify the anemia \[[@B7]\]. Nonetheless, recent evidence has shown that RDW was associated with human diseases, including cardiovascular diseases \[[@B8], [@B9]\], venous thromboses \[[@B10]\], liver diseases, and kidney failures \[[@B11], [@B12]\], as well as with various cancers \[[@B13]\]. Several studies have reported that RDW predicted the mortality of various cancers, including cancers of the lung \[[@B14], [@B15]\], stomach, colon, and endometrium \[[@B16]--[@B18]\]. Thus, there is a close relationship between RDW and cancer mortality. However, evidence of the role of RDW in all-combined cancer remains scarce, and the short-term prognostic value of RDW in terms of mortality remains unclear. Therefore, studying the relationship between RDW and cancer mortality is of great significance for both clinical diagnosis and patient short-term prognosis.

Therefore, we designed this study to evaluate the relationship between RDW and cancer mortality by extracting and analyzing data from the database of MIMIC-III V1.3 and predicting the short-term prognostic value of RDW in all-combined cancer mortality.

2. Methods {#sec2}
==========

2.1. Data Source {#sec2.1}
----------------

Our study was based on the Multiparameter Intelligent Monitoring in Intensive Care Database III version 1.3 (MIMIC-III V1.3), a free public resource. The database includes more than 40,000 pieces of deidentified and health-related data, associated with admissions to Beth Israel Deaconess Medical Center (Boston, MA, USA) between 2001 and 2012 \[[@B19]\]. The database was established by the Massachusetts Institute of Technology (MIT, Cambridge, MA, USA) and Beth Israel Deaconess Medical Center. To protect privacy, all patients were deidentified.

2.2. Population Selection Criteria {#sec2.2}
----------------------------------

A total of 3384 admissions were recorded. Eligible people met the following criteria: older than 18 years of age; malignant tumor confirmed by ICD-9 disease coding; and time of hospitalization \> 2 days. Patients were excluded if \>5% of their individual data were missing or if hospital biopsy revealed hematological malignancy.

2.3. Data Extraction {#sec2.3}
--------------------

We extracted patient data from MIMIC-III V1.3 using Structured Query Language (SQL) with PostgreSQL (version 9.6). The data extracted were patient identifiers, demographic parameters, clinical parameters, and laboratory parameters. Patient identifiers and demographic parameters included age, gender, and ethnicity. We extracted the following clinical parameters: systolic blood pressure (SBP); diastolic blood pressure (DBP); heart rate; respiratory rate; and comorbidities including atrial fibrillation (AF); congestive heart failure (CHF); renal and liver diseases; valvular disease; and stroke and pneumonia. Laboratory parameters extracted included the following: body mass index (BMI); white blood cell count (WBC); platelet count; hematocrit; hemoglobin; blood urea nitrogen (BUN); serum anion gap; bicarbonate; creatinine; and glucose. A sequential organ failure assessment (SOFA) score was also calculated to assess the severity of illness. Hospital mortality was the primary outcome. The baseline characteristics were extracted at 24 h after hospital admission.

2.4. Statistical Analysis {#sec2.4}
-------------------------

Categorical variables were presented as percentage and variances were analyzed by the Chi-square test. Continuous variables were expressed as mean (SD) or IQR and the Kruskal-Wallis test was performed for variance comparisons. The association of RDW and cancer mortality was tested using logistic regression and results were presented as the adjusted odds ratio (OR) and associated 95% confidence interval (CI).

In order to determine whether the RDW was independently associated with cancer mortality, two multivariable analysis models were established on the basis of RDW groups. In model I, we adjusted only for age and gender. In model II, we adjusted for age and gender, as well as for SBP, DBP, BUN, hemoglobin, serum sodium, potassium, platelet, hematocrit, anion gap, renal disease, liver disease, stroke, heart rate, pneumonia, and respiratory rate.

Meanwhile, we performed subgroup analysis to determine whether the effects of RDW varied between various subgroups. Chronic obstructive pulmonary disease (COPD), acute respiratory distress syndrome (ARDS), coronary atherosclerotic heart disease (CAD), and renal replace therapy (RRT) were also included. Our statistical analyses were performed on Empowerstats version 2.17.8 and R software (version 3.42). A two tailed P value \<0.05 was considered statistically significant.

3. Results {#sec3}
==========

3.1. Subject Characteristics {#sec3.1}
----------------------------

A total of 3384 eligible cancer patients were enrolled. According to RDW value, patients were divided into three groups (low, mid, and high). A total of 1117 (33%) patients were in the low-RDW group (11.5 \< RDW \< 14.3), 1112 (32.8%) were in the mid-RDW group (14.4 \< RDW \< 16.3), and 1155 (34.1%) were in the high-RDW group (16.4 \< RDW \< 30.5). Selected characteristics and laboratory data in the RDW groups are displayed in [Table 1](#tab1){ref-type="table"}.

Characteristics such as gender and body mass index (BMI) showed little difference among groups. Patients in the higher RDW group more likely have higher blood pressure, heart rate, and respiratory rate. Patients with higher RDW had more comorbidities, including atrial fibrillation (AF), congestive heart failure (CHF), valvular disease, renal and liver disease, stroke, and pneumonia. They also had higher white blood cell counts (WBC), blood urea nitrogen (BUN), serum anion gap, creatinine, and sequential organ failure assessment (SOFA) scores and were more likely to use renal replacement therapy (RRT) than those with lower RDW. However, platelet count, hematocrit, hemoglobin, serum bicarbonate, and glucose were lower in patients with higher RDW than patients in other groups.

3.2. Association between RDW and Cancer Mortality {#sec3.2}
-------------------------------------------------

We considered RDW as a continuous variable. [Figure 1](#fig1){ref-type="fig"} shows the association between RDW and cancer mortality. A positive correlation was observed, suggesting that patients with higher RDW were at greater risk of cancer mortality.

On multivariate analysis, when we adjusted for age and gender, the adjusted ORs (95% CIs) in the mid-RDW group and high-RDW group were 1.61 (1.28, 2.03) and 2.52 (2.03, 3.13), respectively, and the low-RDW group was set as the baseline (OR (95% CIs) = 1.0). Higher OR (95% CIs) indicated a greater risk of mortality. Meanwhile, RDW was also independently associated with cancer mortality when adjusted for age, gender, BUN, hemoglobin, sodium, potassium, platelet, hematocrit, anion gap, renal disease, liver disease, stroke, heart rate, pneumonia, SBP, DBP, and respiratory rate ([Figure 2](#fig2){ref-type="fig"}, [Table 2](#tab2){ref-type="table"}).

3.3. Subgroup Analyses {#sec3.3}
----------------------

The relationship between RDW and the cancer mortality was similar in most strata ([Table 3](#tab3){ref-type="table"}). Patients in most subgroups had no differences in terms of risk of cancer mortality according to RDW. Significant differences could be observed in COPD and RRT subgroups; patients who had a high RDW only, without COPD or RRT, had a higher risk of cancer mortality, whereas if a patient had COPD or RRT, RDW had little effect on cancer mortality. We also made a subgroup analysis of the types of tumor. We selected three tumors with the highest mortality in the data we extracted from MIMICIII.1.3 database and analyzed the effect of RDW on the mortality of these three tumors by multivariate analysis. The three different types of tumors were lung cancer, gastroenteric tumor, and breast cancer. The associations between RDW and the mortality of three different types of tumors were presented in [Table 4](#tab4){ref-type="table"}. According to the OR (95% CIs) of different groups, RDW can positively affect the mortality of three types of tumors.

4. Discussion {#sec4}
=============

We found a positive correlation between RDW and cancer mortality, with higher RDW associated with increased risk of cancer mortality, showed RDW may be used to predict the mortality of tumor and the risk assessment of tumor patients. On multivariate analysis, the model only adjusting for age and gender suggested that higher RDW correlated with increased risk of hospital mortality. Similar trends could also be observed in the model adjusted for a greater number of characteristics, suggesting that RDW may be an effective tumor prognostic factor. Although several previous studies suggested that RDW was associated with mortality in various cancers \[[@B14]--[@B18], [@B20], [@B21]\], evidence to solidify the relationship remains rare. Moreover, most studies only demonstrated associations between the RDW and a single type of cancer; the relationship between RDW and all-combined cancer mortality remains unclear, and the role of RDW in tumor short-term prognosis is also very vague. Therefore, we evaluated the relationship between RDW and all-cancer mortality and proved the effect of RDW in tumor short-term prognosis.

There are many factors affecting the risk of cancer mortality. Our study demonstrated that RDW was an independent risk factor using multivariate analysis and adjusting for age and gender. This has substantial implications for clinical diagnosis and patient short-term prognosis. Given the results of our study, a positive relationship could be observed, and patients with higher RDW had an increased mortality rate. On subgroup analysis, we found the same positive correlation between RDW and cancer mortality in most strata. We infer that RDW could be a major short-term prognostic marker of hospital mortality for cancer patients. However, the explanations and mechanisms for the relationship between RDW and cancer mortality require more research to clarify.

Many studies have shown that inflammation was associated with tumor progression and metastasis \[[@B22]--[@B24]\]. Recently, RDW was reported as an emerging novel biomarker for systemic inflammation \[[@B25], [@B26]\]. Many other hematological parameters, including neutrophil/lymphocyte ratio (NLR) \[[@B27], [@B28]\], platelet/lymphocyte ratio (PLR) \[[@B28]\], lymphocyte/monocyte ratio \[[@B29]\], C-reactive protein \[[@B27]\], and interleukin-6 \[[@B30]\], all closely related to the inflammatory response and anemia, also have been reported to play a prognostic role in cancers. In addition, the RDW can be used as an important index for early diagnosis of iron deficiency anemia and may provide reference for clinical prevention of iron deficiency anemia \[[@B31]\]. Meanwhile, some studies reported that anemia was related to worse outcome in some type of cancers \[[@B31]--[@B33]\]. Anemia could also be caused by a systemic inflammation response in some cancers \[[@B34]\]. Therefore, we speculate that RDW could affect cancer mortality by influencing the inflammatory reaction and anemia. Further study should be conducted to test this hypothesis.

The primary strength of the present study is that we demonstrated a relationship between RDW and all-combined cancer mortality, with significant implications for clinical prognosis and the short-term prognosis of cancer patients. In addition, we used a free public database MIMIC-III V1.3 and extracted and analyzed sufficient patient data.

Nevertheless, there were a few limitations to this study. First, our analysis was a single-center retrospective analysis. Therefore, more prospective multicenter studies are needed. Second, RDW was measured only after admission, and a single measurement of RDW was not sufficient to reflect the degree of heterogeneity of erythrocyte volume. Third, we did not establish a predictive model for analyzing the relationship between RDW and cancer mortality, requiring further investigation. Finally, individual patient data were missing and outliers were present, possibly influencing our results.

5. Conclusions {#sec5}
==============

We found a positive correlation between RDW and cancer mortality by extracting and analyzing a large amount of data, indicating that increased RDW was related to high-risk of mortality. RDW was an independent prognostic indicator of short-term mortality after hospitalization in cancer patients.
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###### 

Baseline characteristics of the study population.

  **Characteristics**                 **RDW (**%**)**   **P-value**                     
  ----------------------------------- ----------------- --------------- --------------- ---------
  RDW start                           13.5 ± 0.6        15.2 ± 0.6      18.2 ± 1.6      \<0.001
  Clinical parameters, n (%)          1117              1112            1155             
  Age, years                          64.7 ± 14.9       68.2 ± 13.9     67.0 ± 14.3     \<0.001
  Gender, n (%)                                                                         0.533
   Male                               487 (43.6)        493 (44.3)      530 (45.9)       
   Female                             630 (56.4)        619 (55.7)      625 (54.1)       
  Ethnicity, n (%)                                                                      0.015
   White                              812 (72.7)        838 (75.4)      840 (72.7)       
   Black                              72 (6.4)          76 (6.8)        109 (9.4)        
   Other                              233 (20.9)        198 (17.8)      206 (17.8)       
  SBP, mmHg                           119.3 ± 15.5      118.1 ± 16.7    115.2 ± 16.6    \<0.001
  DBP, mmHg                           61.8 ± 9.7        60.5 ± 10.3     59.8 ± 10.5     \<0.001
  Heart rate, beats/minute            87.7 ± 16.1       90.1 ± 16.2     92.1 ± 17.4     \<0.001
  Respiratory rate, beats/minute      18.9 ± 4.3        19.7 ± 4.5      20.0 ± 4.4      \<0.001
  Comorbidities                                                                          
   Atrial fibrillation, n (%)         273 (24.4)        324 (29.1)      342 (29.6)      0.010
   Congestive heart failure, n (%)    92 (8.2)          156 (14.0)      160 (13.9)      \<0.001
   Renal disease, n (%)               63 (5.6)          128 (11.5)      158 (13.7)      \<0.001
   Liver disease, n (%)               37 (3.3)          80 (7.2)        95 (8.2)        \<0.001
   Valvular disease, n (%)            380 (34.0)        415 (37.3)      462 (40.0)      0.013
   Stroke, n (%)                      112 (10.0)        93 (8.4)        77 (6.7)        0.015
   Pneumonia, n (%)                   307 (27.5)        357 (32.1)      358 (31.0)      0.046
  Laboratory parameters                                                                  
   Body mass index, kg/m^2^           27.3 ± 5.8        27.7 ± 6.3      27.6 ± 5.7      0.524
   White blood cell count, 10^9^ /L   12.5 ± 6.7        13.1 ± 11.0     15.1 ± 26.9     \<0.001
   Platelet count, 10^9^ /L           246.7 ± 121.5     239.6 ± 149.0   224.1 ± 171.1   0.001
   BUN, mg/dl                         20.9 ± 15.6       27.6 ± 22.5     31.8 ± 25.0     \<0.001
   Serum potassium, mmol/L            4.2 ± 0.5         4.2 ± 0.6       4.2 ± 0.6       0.028
   Hemoglobin, g/dl                   11.4 ± 1.8        10.5 ± 1.7      9.8 ± 1.6       \<0.001
   Hematocrit, %                      33.6 ± 5.3        31.2 ± 5.1      29.6 ± 4.9      \<0.001
   Serum anion gap, mmol/L            13.9 ± 3.0        14.3 ± 3.8      14.9 ± 3.9      \<0.001
   Serum bicarbonate, mmol/L          23.9 ± 3.9        23.5 ± 4.5      22.9 ± 4.6      \<0.001
   Serum creatinine, mg/dl            1.1 ± 0.8         1.4 ± 1.6       1.4 ± 1.3       \<0.001
   Serum glucose, mg/dl               148.3 ± 52.9      144.6 ± 47.4    141.0 ± 55.4    0.004
  Scoring systems                                                                        
   SOFA                               3.8 ± 2.8         4.7 ± 3.1       5.5 ± 3.5       \<0.001
  Hospital expire                     145 (13.0)        222 (20.0)      321 (27.8)      \<0.001
  Renal replace therapy               34 (3.0)          49 (4.4)        80 (6.9)        \<0.001

BUN: blood urea nitrogen, SBP: systolic blood pressure, DBP: diastolic blood pressure, and SOFA: sequential organ failure assessment. Normally distributed data are presented as the mean (SD) (analysis of variance); nonnormally distributed data are presented as median (IQR) (nonparametric Wilcoxon test); and categorical variables are presented as n (%) (Chi-square test).

###### 

OR (95% Cls) for all-cause mortality across fitted groups of RDW (fitted groups: model 1 and model 2).

  ---------------------------------------------------------------------------------------------
  **Exposure**             **Non-adjusted**       **Adjust I**           **Adjust II**
  ------------------------ ---------------------- ---------------------- ----------------------
  Clinical parameters, n   3384                   3384                   3346

  RDW start group                                                         

   11.5 - 14.3             1.0                    1.0                    1.0

   14.4- 16.3              1.67 (1.33, 2.10)  \   1.61 (1.28, 2.03)  \   1.23 (0.95, 1.60)  \
                           \<0.0001               \<0.0001               0.1153

   16.4- 30.5              2.58 (2.08, 3.20)  \   2.52 (2.03, 3.13)  \   1.66 (1.28, 2.16)  \
                           \<0.0001               \<0.0001               0.0002

  RDW start group trend    1.24 (1.18, 1.31)  \   1.24 (1.18, 1.30)  \   1.13 (1.06, 1.20)  \
                           \<0.0001               \<0.0001               0.0001
  ---------------------------------------------------------------------------------------------

Table data: *β* (95%CI) P value / OR (95%CI) P value.

Outcome: hospital mortality.

Exposure: RDW group; RDW group trend.

Nonadjusted model adjust for none.

Adjust I model adjust for age; gender.

Adjust II model adjust for age; gender; heart rate; respiratory rate; liver disease; CAD; stroke; pneumonia; valvular disease; serum sodium; serum potassium; platelet count; crematory; anion gap; serum bicarbonate; SOFA; SIRS; renal replace therapy; scoring system.

###### 

Subgroup analysis of the associations between cancers mortality and the RDW.

  **RDW**                          **N**   **OR (95% Cls)**    **P value**
  -------------------------------- ------- ------------------- -------------
  Age, years                                                    
   19.3 - 61.0                     1143    1.24 (1.17, 1.30)   \<0.0001
   61.0 - 74.3                     1143    1.15 (1.09, 1.22)   \<0.0001
   74.3 - 91.4                     1144    1.08 (1.02, 1.14)   0.0066
  Sex, n (%)                                                    
   Male                            1530    1.16 (1.11, 1.21)   \<0.0001
   Female                          1900    1.15 (1.10, 1.20)   \<0.0001
  Ethnicity, n (%)                                              
   White                           261     1.20 (1.08, 1.34)   0.0007
   Black                           2520    1.16 (1.11, 1.20)   \<0.0001
   Other                           649     1.15 (1.08, 1.24)   0.0001
  SBP, mmHg                                                     
   71.5 - 108.3                    1139    1.16 (1.11, 1.22)   \<0.0001
   108.3 - 122.9                   1140    1.16 (1.09, 1.23)   \<0.0001
   122.9 - 176.6                   1140    1.10 (1.04, 1.17)   0.0013
  DBP, mmHg                                                     
   27.9 - 55.8                     1139    1.18 (1.12, 1.25)   \<0.0001
   55.8 - 64.4                     1138    1.12 (1.06, 1.18)   \<0.0001
   64.4 - 103.8                    1141    1.15 (1.09, 1.22)   \<0.0001
  Hematocrit, %                                                 
   18.1 - 31.1                     1120    1.09 (1.04, 1.14)   0.0007
   31.2 - 35.9                     1130    1.20 (1.13, 1.27)   \<0.0001
   36 - 66.7                       1179    1.24 (1.16, 1.33)   \<0.0001
  Hemoglobin, g/dl                                              
   6.1 - 10.3                      1126    1.08 (1.03, 1.14)   0.0012
   10.4 - 12                       1141    1.19 (1.13, 1.27)   \<0.0001
   12.1 - 21.5                     1162    1.22 (1.13, 1.31)   \<0.0001
  Respiratory rate, beats/minute                                
   9.9 - 17.2                      1139    1.22 (1.14, 1.30)   \<0.0001
   17.2 - 20.8                     1138    1.12 (1.06, 1.19)   0.0001
   20.8 - 42.2                     1139    1.12 (1.07, 1.18)   \<0.0001
  Serum bicarbonate, mmol/L                                     
   6 - 22                          945     1.13 (1.07, 1.19)   \<0.0001
   23 - 25                         1078    1.23 (1.15, 1.31)   \<0.0001
   26 - 46                         1403    1.11 (1.05, 1.16)   0.0001
  Congestive heart failure                                      
   0                               3018    1.16 (1.13, 1.20)   \<0.0001
   1                               412     1.11 (1.01, 1.22)   0.0362
  Atrial fibrillation                                           
   0                               2478    1.17 (1.13, 1.22)   \<0.0001
   1                               952     1.11 (1.05, 1.18)   0.0004
  COPD                                                          
   0                               3337    1.16 (1.13, 1.20)   \<0.0001
   1                               93      0.99 (0.78, 1.24)   0.9016
  Respiratory failure                                           
   0                               1995    1.16 (1.10, 1.22)   \<0.0001
   1                               1435    1.17 (1.12, 1.22)   \<0.0001
  ARDS                                                          
   0                               3351    1.15 (1.12, 1.19)   \<0.0001
   1                               79      1.30 (1.07, 1.56)   0.0069
  Pneumonia                                                     
   0                               2392    1.18 (1.13, 1.23)   \<0.0001
   1                               1038    1.13 (1.07, 1.19)   \<0.0001
  Valvular disease                                              
   0                               2160    1.13 (1.08, 1.18)   \<0.0001
   1                               1270    1.20 (1.14, 1.26)   \<0.0001
  CAD                                                           
   0                               2907    1.16 (1.12, 1.20)   \<0.0001
   1                               523     1.13 (1.03, 1.23)   0.0102
  Stroke                                                        
   0                               3145    1.16 (1.12, 1.20)   \<0.0001
   1                               285     1.15 (1.03, 1.29)   0.0107
  Renal disease                                                 
   0                               3075    1.16 (1.12, 1.20)   \<0.0001
   1                               355     1.13 (1.02, 1.24)   0.0192
  Liver disease                                                 
   0                               3213    1.16 (1.12, 1.20)   \<0.0001
   1                               217     1.13 (1.01, 1.26)   0.0343
  Renal replace therapy                                         
   0                               3259    1.16 (1.12, 1.20)   \<0.0001
   1                               171     1.06 (0.96, 1.18)   0.2569

SBP: systolic blood pressure, DBP: diastolic blood pressure, COPD: chronic obstructive pulmonary disease, ARDS: acute respiratory distress syndrome, and CAD: coronary atherosclerotic heart disease.

ORs (95% CIs) were derived from logistic regression analysis models.

###### 

Subgroup analysis of the associations between the mortality of three different types of tumors and the RDW.

  **RDW start group**   **Lung cancer**     **Gastroenteric tumor**   **Breast cancer**
  --------------------- ------------------- ------------------------- -------------------
  11.5 - 14.3           1.0                 1.0                       1.0
  14.4- 16.3            1.19 (0.94, 1.53)   1.51 (1.26, 1.90)         1.28 (1.12, 1.79)
  16.4- 30.5            1.89 (1.36, 2.29)   2.01 (1.89,2.31)          1.56 (1.41,1.91)

ORs (95% CIs) were derived from logistic regression analysis models.
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